Crescent Biopharma (CBIO) stock, explained like you're 5

Is Crescent Biopharma a small, medium or large cap company?

No. Crescent Biopharma is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 554 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Crescent Biopharma makes money

• Selling medicines, medical devices or healthcare services.
• Insurance premiums or hospital and clinic fees.
• Research and licensing deals.

What moves CBIO stock

• Results from clinical trials and approvals from regulators.
• Drug prices, insurance rules and government policy.
• Patents running out and new competing treatments.

In the news lately

• symbol__ Stock Quote Price and Forecast (CNN)
• Stifel reiterates Crescent Biopharma stock rating on pipeline progress (Investing.com)
• More than 125 patients have received an experimental cancer drug. It’s now being tested with chemotherapy. (Stock Titan)
• $CBIO stock is down 14% today. Here's what we see in our data. (Quiver Quantitative)
• FDA clears CR 002 for human testing as Crescent Biopharma (CBIO) prepares to start its trial. (Stock Titan)

Key terms to know before you follow CBIO

• Market cap
• P/E ratio
• EPS (earnings per share)
• Earnings report
• Volatility